PDCD1 and non-small cell lung carcinoma: This systematic review will be conducted to clarify essential details associated with anti-PD-1 and anti-PD-L1 drugs in the treatment of NSCLC and the findings of the review may facilitate early prediction, comprehensive observation, and prompt management of irAEs in addition to better patient compliance.